Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has maintained a Buy rating on Seres Therapeutics (NASDAQ:MCRB) but has lowered the price target from $10 to $8.

March 06, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Chardan Capital maintains a Buy rating on Seres Therapeutics but lowers the price target from $10 to $8.
While the reduction in price target could suggest a tempered outlook on the stock's potential upside, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal might lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the reaffirmed positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100